about
Advancing the Minimal Residual Disease Concept in Acute Myeloid LeukemiamiR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with RituximabMaintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet.Biology of multiple drug resistance in acute leukemia.Targeting autophagy potentiates the apoptotic effect of histone deacetylase inhibitors in t(8;21) AML cells.Presence of clone-specific markers at birth in children with acute lymphoblastic leukaemia.Changing picture of cellular drug resistance in human leukemia.Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML.Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA).Identification and cloning of a prethymic precursor T lymphocyte from a population of common acute lymphoblastic leukemia antigen (CALLA)-positive fetal bone marrow cellsSomatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer.Analysis of leucocyte differentiation antigens in blood and bone marrow in patients with refractory anaemia (RA) and RA with sideroblasts. Prognostic implications of sequential and follow-up data.Stereological analysis of the ultrastructure in isolated human T and non-T lymphoid cells. I. Description of method and data on normal blood lymphocytes.Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target.Towards individualized follow-up in adult acute myeloid leukemia in remission.Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation.A highly sensitive and specific qPCR assay for quantification of the biomarker SOX11 in mantle cell lymphoma.IFN-induced modulation of histocompatibility antigens on human cells. Background, mechanisms and perspectives.Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age.Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript.Delineation and molecular characterization of acute myeloid leukemia patients with coduplication of FLT3 and MLL.ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma.Cholinergic activation enhances retinoic acid-induced differentiation in the human NB-4 acute promyelocytic leukemia cell line.Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas.Combination of RNA- and exome sequencing: Increasing specificity for identification of somatic point mutations and indels in acute leukaemia.Nonviral transfection of leukemic primary cells and cells lines by siRNA-a direct comparison between Nucleofection and Accell delivery.Detection of mutations in GC-rich DNA by bisulphite denaturing gradient gel electrophoresis.Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene.Functional characterization in vitro of two human T-cell subpopulations with different affinities to sheep erythrocytes.The human mixed lymphocyte reaction responder and stimulator capacities of highly purified T- and non-T cells and the role of monocytes.Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma.A pharmacodynamic study of 5-azacytidine in the P39 cell line.Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite [corrected] extensive proliferation.
P50
Q28087291-E852F2B6-A772-436A-AA82-570E8068F3F7Q30496174-9AB9E1EC-1F59-4752-AF82-3CDF4491F3E4Q31012437-A249F849-1786-4EDC-948C-6DA1CDF50835Q31150752-1F238AE6-E58D-414A-9D58-843FE041007CQ33389755-82DB106A-D859-433D-9D5E-B2F692A9FEB1Q33873297-D622B75E-0397-4977-AB0C-E95690E13718Q34143670-DFF700CF-DB00-4BB2-9E9E-CCFD6568E8D1Q34366048-26A78271-6E16-4F32-919B-79F2495CDABCQ34998698-5541913F-693B-4AD9-8469-4CA838E66E69Q35749778-29715800-1D2F-42ED-884A-52E557F444D0Q36177937-9C099E40-81DC-4FC3-A7C8-B5579DD97F99Q36347276-3E560E99-F7EC-4309-84F8-50C53F30DE52Q36352686-CBC6C63C-CA99-4B40-BECE-9B8DBE90A4DCQ36385656-96038A37-A7DE-4399-A556-5B2FA4FF375BQ36438551-44A26D6E-7322-4F5A-836D-6685ED646CCEQ36588027-612A2853-0A16-43EC-B6A6-3B6CC46AAA2DQ36964344-CD823606-B9B1-4B3C-8197-77A6FB86DFE1Q37200863-4696FF65-A408-4F60-80BB-9026D1CAE30AQ37263168-A942C833-4222-4091-954F-8F40DAE4255DQ37322437-68C97AC9-5697-4C4B-9E30-27ADE29314B9Q37811623-C8183A6B-183A-4F3A-AAF0-14ADA6B6D5ABQ38022075-2EF9B2D2-C4D7-4FD0-B96E-0A5B4A02E86BQ38029095-FA911E0A-6319-4CA8-BB76-182553BF6B98Q38198500-1322CE39-DE99-44AE-8003-51B872455B4EQ38240563-4DC2DC86-8676-4D10-8B9F-AB6D485C9347Q38319141-8B8F47CF-1C8C-4BAA-895E-630C26A267A2Q38322066-83DC2C51-4DE5-405A-A447-047810366E8FQ38363906-D878766A-9D43-4746-B518-E68A4EE4D5CEQ38765430-964454C5-F68B-4E41-A976-60CFD187BD88Q39015297-7770E020-E1DD-4CD9-867C-9D686C823782Q39207882-0FEC07D7-D129-479C-BC3C-1C0F9CAFF6A1Q39487538-266471AB-0D42-40A2-BD1B-0DB7D7366920Q39723300-A44AC4C0-2D77-4D13-B62D-64E99F1215DAQ39862735-7DDB80B5-C647-4CA1-87B1-35A4C88E7604Q39883887-98A65275-6F2A-4DB0-8E35-41EED72F4A16Q39895012-4AD08752-5890-4619-9AA7-5D991D61052BQ39930852-ACCF080A-497B-4529-A507-EA97E4A63A63Q40047438-A9C31F65-A072-4697-AC71-FC34510950BCQ40329694-D113251C-7980-4E19-8B1E-C0C78CCB4168Q40481324-C6C26C75-7E0E-4B30-A1F8-4EC38F82D9A2
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Peter Hokland
@ast
Peter Hokland
@en
Peter Hokland
@es
Peter Hokland
@nl
Peter Hokland
@sl
type
label
Peter Hokland
@ast
Peter Hokland
@en
Peter Hokland
@es
Peter Hokland
@nl
Peter Hokland
@sl
prefLabel
Peter Hokland
@ast
Peter Hokland
@en
Peter Hokland
@es
Peter Hokland
@nl
Peter Hokland
@sl
P214
P106
P1153
7005638324
P21
P214
P31
P496
0000-0002-1177-9756
P735
P7859
viaf-231221897